Reviewed by Julie Boora, Superintendent Pharmacist, TribElle Health Ltd (GPhC Reg. 9012688)
| 10M+ UK migraine sufferers | #3 Most disabling condition worldwide | 2026 Updated SIGN guidance |
Migraines affect more than 10 million people across the UK and remain one of the most common neurological conditions worldwide. For many individuals, migraine attacks can significantly impact work, sleep, mental wellbeing, family life, and overall quality of life.
The updated SIGN migraine guidance for 2026 introduces important recommendations designed to improve migraine diagnosis, treatment, prevention, and long-term management.
The latest guidance reflects a growing understanding that migraine is not "just a headache" — it is a complex neurological condition requiring personalised, evidence-based care.
Quick answer
The primary goal of the new SIGN migraine guidance is to improve migraine outcomes through earlier diagnosis, evidence-based treatment, preventative care, and better long-term management strategies.
The Scottish Intercollegiate Guidelines Network (SIGN) updated its migraine recommendations to reflect the latest clinical evidence surrounding:
Migraine is a neurological condition that can cause a wide range of symptoms. Attacks may last from several hours to multiple days and vary significantly between individuals.
|
Common symptoms
|
Also common
|
The updated SIGN guidance reinforces the importance of recognising migraine as a serious health condition that often requires ongoing management rather than occasional symptom treatment.
The updated recommendations place greater emphasis on three areas:
| 1 |
Early and accurate diagnosis Many migraine sufferers experience delayed diagnosis or confusion with other headache disorders. The guidance encourages clinicians to improve diagnostic accuracy by identifying common migraine patterns, triggers, and associated neurological symptoms earlier. |
| 2 |
Preventative migraine treatment Preventative therapies are increasingly recommended for people experiencing frequent or disabling migraine attacks. The guidance highlights the importance of considering preventative treatment when migraines significantly affect:
|
| 3 |
Avoiding medication overuse headaches Frequent use of painkillers can sometimes worsen headaches over time. The updated recommendations stress the importance of reviewing medication use carefully to reduce the risk of medication overuse headaches, which can become difficult to manage long term. |
The SIGN update supports a combination of medical and non-medical migraine management approaches.
|
Acute treatments For immediate symptom relief, clinicians may consider:
|
Preventative treatment Preventative medication may help reduce:
|
The guidance also highlights the importance of identifying and managing common migraine triggers:
Keeping a migraine diary may help you identify patterns and improve self-management — and is something many clinicians now recommend as part of a personalised care plan.
One of the most important themes in the updated guidance is the move toward holistic, patient-centred care. Migraine is closely linked with broader health factors:
|
|
||||
|
|
The updated guidance encourages patients to seek professional support if they experience:
Seek professional support if you notice:
|
|
||||
|
|
||||
|
|
As migraine care evolves, TribElle supports a modern approach that reflects the latest guidance:
|
|
||||
|
|
If you've been diagnosed with migraine, there are several ways to access treatment depending on the severity and frequency of your symptoms.
For occasional migraines, many UK online pharmacies, including TribElle, can assess your suitability for acute prescription treatments such as triptans following an online consultation with a UK-registered prescriber.
However, if you're experiencing frequent or disabling migraines, you may benefit from assessment by a specialist headache clinic or neurologist.
According to UK clinical guidance, chronic migraine is defined as experiencing:
People living with chronic migraine often require preventive treatment rather than medication taken only during an attack. Specialist assessment can help determine which treatment options may be most appropriate.
If your migraines occur frequently or significantly affect your quality of life, a specialist may recommend preventive treatment to reduce the number and severity of migraine attacks.
Depending on your medical history and previous treatments, options may include:
Common first-line preventive medicines include:
These medicines are taken regularly to help reduce migraine frequency rather than treating an individual attack.
Botulinum toxin may be recommended for adults with chronic migraine who have not responded to, or cannot tolerate, at least three preventive medicines. Treatment is administered by trained specialists and is usually repeated approximately every 12 weeks.
Calcitonin Gene-Related Peptide (CGRP) therapies have transformed migraine prevention for many people living with chronic migraine.
Depending on clinical eligibility, these treatments may include:
These medicines work by blocking the CGRP pathway involved in migraine attacks and are typically prescribed by specialist headache services.
Atogepant is an oral CGRP receptor antagonist used for migraine prevention in eligible patients and may be prescribed in accordance with current NICE guidance.
People who meet NICE eligibility criteria may be referred by their GP to a neurologist or specialist headache clinic for advanced migraine treatments such as Botox® or CGRP-targeted medicines.
Waiting times vary across the UK depending on local services.
Private headache clinics and consultant neurologists may offer earlier access to specialist assessment and advanced migraine treatments where clinically appropriate.
Private treatment may be suitable for people seeking faster access to specialist advice or those wishing to explore additional treatment options.
TribElle is a UK-registered online pharmacy specialising in women's health. While we do not currently provide specialist chronic migraine management, we support women experiencing episodic migraine by offering convenient online consultations for suitable acute migraine treatments, alongside trusted clinical advice and educational resources.
If your migraine symptoms are becoming more frequent, your medication is no longer effective, or you're experiencing headaches on 15 or more days each month, we recommend speaking to your GP or requesting referral to a specialist headache service for further assessment.
Migraines are believed to involve complex neurological, genetic, hormonal, and environmental factors. Triggers vary between individuals and can include stress, sleep disruption, hormonal changes, dehydration, certain foods, and excessive screen use.
Yes. Many people with migraines have a family history of the condition, suggesting a strong genetic component. However, environmental and lifestyle factors also play a significant role in how often and how severely migraines occur.
Aura refers to neurological symptoms that may occur before or during a migraine attack, such as visual disturbances, numbness, tingling, or speech difficulties. Not all people with migraines experience aura.
Preventative treatment may be recommended if migraines occur frequently, significantly affect daily life, work, sleep, or mental wellbeing, or if acute medication is becoming less effective. The updated SIGN guidance encourages earlier consideration of preventative options rather than waiting until migraines become severely disabling.
Yes. Improving sleep, hydration, stress management, and trigger awareness can help reduce migraine frequency and severity. The updated SIGN guidance places significant emphasis on lifestyle management as part of a holistic, long-term migraine care plan.
Bottom line
The updated SIGN migraine guidelines for 2026 represent an important step forward in improving migraine care across the UK. By focusing on earlier diagnosis, preventative treatment, safer medication use, and holistic support, the guidance encourages a more effective and compassionate approach to migraine management.
For patients living with migraines, this means greater recognition of the condition's impact and more personalised support strategies designed to improve long-term quality of life.
Managing migraines starts with having the right products to hand. Here's what we stock at TribElle.
| Nurofen 200mg Caplets £2.77 |
| 4Head Migraine QuickStrips £5.00 |
© TribElle Health Ltd · GPhC Registration 9012688 · tribelle.co.uk · This content is for informational purposes only. Always consult a qualified healthcare professional.
Explore treatments
Hormone-aware migraine care and prescription options, reviewed by clinicians.
See migraine treatments →Join the conversation
|
|||
|